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Abstract
Background: The pathway-focused association approach offers a hypothesis driven alternative to the agnostic genome-
wide association study. Here we apply the pathway-focused approach to an association study of hypertension, systolic
blood pressure (SBP), and diastolic blood pressure (DBP) in 1614 Nigerians with genome-wide data.
Methods and Results: Testing of 28 pathways with biological relevance to hypertension, selected a priori, containing a total
of 101 unique genes and 4,349 unique single-nucleotide polymorphisms (SNPs) showed an association for the adrenergic
alpha 1 (ADRA1) receptor pathway with hypertension (p,0.0009) and diastolic blood pressure (p,0.0007). Within the
ADRA1 pathway, the genes PNMT (hypertension Pgene,0.004, DBP Pgene,0.004, and SBP Pgene,0.009, and ADRA1B
(hypertension Pgene,0.005, DBP Pgene,0.02, and SBP Pgene,0.02) displayed the strongest associations. Neither ADRA1B nor
PNMT could be the sole mediator of the observed pathway association as the ADRA1 pathway remained significant after
removing ADRA1B, and other pathways involving PNMT did not reach pathway significance.
Conclusions: We conclude that multiple variants in several genes in the ADRA1 pathway led to associations with
hypertension and DBP. SNPs in ADRA1B and PNMT have not previously been linked to hypertension in a genome-wide
association study, but both genes have shown associations with hypertension through linkage or model organism studies.
The identification of moderately significant (10
22.p.10
25) SNPs offers a novel method for detecting the ‘‘missing
heritability’’ of hypertension. These findings warrant further studies in similar and other populations to assess the
generalizability of our results, and illustrate the potential of the pathway-focused approach to investigate genetic variation
in hypertension.
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Introduction
The high prevalence [1] and heritability [2] of hypertension
made it a target for genome-wide association study (GWAS) after
the completion of the Human Genome Project, with the hope of
developing diagnostic tools or gene-based designer drugs [3].
GWAS have led to the discovery of many single nucleotide
polymorphisms (SNPs) associated with various traits and diseases
[4]. However, the stiff penalties for testing hundreds of thousands
of SNPs may obscure true associations, and GWAS have an
increased chance for finding false positive associations if
underpowered [5]. The results of hypertension GWAS in
particular have been relatively disappointing [6], revealing a
small number of SNPs with modest effect sizes. Proposed
explanations for the lack of success include the need to identify
rare variants with large effect sizes, lack of statistical power to
detect common variants with very small effect sizes, error
associated with phenotyping, and complex genetic interaction
networks.
Due to the relative lack of success of GWAS, alternative
methods of identifying the genetic underpinnings of hypertension
are being explored, including pathway analysis of GWAS results
[7] and targeting of candidate genes [8]. The former approach is
a traditional GWAS with the addition of an algorithm that
identifies biological pathways with more significant SNPs than
would be expected by chance. The latter approach uses genes
that have been identified as related to the disease in animal
models, Mendelian forms of the disease, or through previous
association studies. Both of these approaches have limitations.
Pathway analysis of GWAS results can identify pathways that
defy biological explanation, while candidate gene studies cannot
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include all genes involved in the pathway.
Our study used a pathway-focused approach to identify
common variants associated with hypertension in biologically
relevant pathways, which minimizes the limitations of aforemen-
tioned alternatives to GWAS. Pathways with biological relevance
to hypertension were identified first, with an emphasis on signal
transduction and pathways with therapeutic targets, and the
analysis was limited to only SNPs within these pathways.
Subsequently, the pathways were analyzed to identify excesses of
moderately significant (10
22.p.10
25) SNPs; the analysis was
niether intended nor powered to detect individual SNPs reaching
genome-wide significance. The pathway-focused approach has
previously been used with success in three inflammatory diseases.
[9] A priori identification of biologically-relevant pathways ensured
ease of interpretation and minimized multiple-testing penalties.
We applied the pathway-focused approach to study hypertension,
diastolic blood pressure (DBP), and systolic blood pressure (SBP) in
a sample of 1614 adult Nigerians, and identified an association for
the adrenergic alpha 1 pathway.
Methods
Participant recruitment
Study participants were recruited from Yoruba-speaking
communities in southwest Nigeria as part of a long-term study
on the environmental and genetic factors underlying hypertension
[10]. The sample is comprised of unrelated adults with normal or
elevated blood pressure from Igbo-Ora, a rural town with a
population of about 50,000; and from Idikan, a low-income
neighborhood in the near-by city of Ibadan. The participants from
Idikan were controls in the Africa-America Diabetes Mellitus
(AADM) Study recruited from Ibadan [11]. Both towns are in
similar neighborhoods.
Ethics Statement
Both projects were reviewed and approved by the Institutional
Review Board of the sponsoring US institutions (Loyola University
Chicago and Howard University) and the Joint Ethical Committee
of the University of Ibadan/University College Hospital, Ibadan,
Nigeria. All participants signed informed consent administered in
either English or Yoruba, which is the native language.
Phenotype measurement
A screening exam was completed by trained and certified
research staff using a standardized protocol [10,12]. Information
was obtained on medical history, age, body weight and height.
Body weight was measured to the nearest 0.2 kg on calibrated
electronic scales, whereas height was obtained using a stadiometer
consisting of a steel tape attached to a straight wall and a wooden
headboard. The headboard was positioned with the participant
shoeless, feet and back against the wall, and head held in the
Frankfort horizontal plane and measurement taken to the nearest
0.1 cm. Body mass index (BMI) was calculated as the ratio of
weight in kilograms to the square of height in meters. An
oscillometric device, previously evaluated in our field settings, was
used for all BP measurements [12]. Three measurements were
taken three minutes apart and the average of the final two was
used in the analysis. Individuals with systolic blood pressure (SBP)
$140 mmHg, diastolic blood pressure (DBP) $90 mmHg or on
anti-hypertensive medication at time of exam were defined as
hypertensives. Participants with hypertension were offered treat-
ment after detection at the screening exam.
Genotyping and quality assessment
Data used in the present analysis were extracted from curated
quality controlled genotype data on 1614 unrelated hypertensive
or normotensive adults genotyped on the Affymetrix Genome-
Wide Human SNP array 6.0. Descriptions of the genotyping and
quality control of the genotype data have been provided elsewhere
[13]. Briefly, 1253 DNA samples were genotyped on the
Affymetrix Genome-Wide Human SNP array 6.0 at the Broad
Institute, Cambridge, MA. The chip analysis provided data on
909,622 SNPs. Four samples were excluded because of discor-
dance between reported gender and observed gender from the
genotype data. Samples with inbreeding coefficients outside of four
standard deviations of the mean coefficient were removed (n=11)
as well as samples sharing high IBD proportion either due to
sample contamination (n=14), duplicates (n=18), or cryptic
relatedness (n=1). Additional samples identified as outliers based
on multidimensional scaling analysis of the genome-wide IBD
pairwise distances (n=12), or clustering of missing genotypes
(n=5) were dropped. As part of quality control procedure, SNPs
with a proportion of missing genotypes .0.05 (n=34137) or with
MAF ,1% (n=64955) or failing HWE test at P,1.0610
26
(n=16616) were all excluded. In addition, genotypes for 1,035
SNPs found to exhibit substantial deviations associated with assay
plates or batch effects were dropped. The resulting quality
controlled clean dataset consisted of 1,188 subjects with genotypes
on 759,215 SNPs. We did not observe significant evidence of
population stratification among the samples.
To increase the sample size, an additional batch of 449 samples,
selected from the same cohort as the first batch, was genotyped on
same Affymetrix Genome-Wide Human SNP array 6.0. This
batch was similarly processed using standard quality control
procedure. SNPs with a proportion of missing genotypes .0.05
(n=25090) or with MAF ,1% or failing HWE test at
P,1.0610
26 (n=68205) or with significant plate effect (n=188)
or significant differential missingness by phenotype status (n=86)
were excluded. Also, samples with inbreeding coefficients outside
of four standard deviations of the mean coefficient (n=2) and
samples identified as outliers based on multidimensional scaling
analysis of the genome-wide IBD pairwise distances (n=6) were
dropped. The number of samples that passed quality control was
441, of which 15 samples were replicates from the first batch. We
assessed concordance between both batches of genotyping using
the data on 15 samples replicated in both and observed
concordance rate of 0.997876. For the present study, we combined
data on the 426 unique samples from the second batch with data
on 1188 samples from the first batch. Prior to merging both
datasets, all excluded SNPs in batch one data were also excluded
from batch two data. The final cleaned dataset thus consisted of
1614 unrelated adult hypertensive (n=790) and normotensive
(n=824) subjects, 940 females and 674 males with 759,215 SNPs
across both the 22 autosomal and X chromosomes. There was no
significant evidence of population stratification.
Pathway Selection and Construction
Genes in pathways related to the renin-angiotensin-aldosterone
system and vascular smooth muscle cell (VSMC) contraction were
selected using KEGG (http://www.genome.jp/kegg/pathway.
html) and Biocarta (http://biocarta.com/genes/allpathways.asp).
Other pathways related to hypertension were selected from the
literature, with an emphasis on signal transduction and pathways
with therapeutic targets. A total of 28 pathways, 101 unique genes,
and 4,349 unique SNPs was included in the study (Table S1).
Release of calcium from the sarcoplasmic reticulum (SR) was
chosen as the end-point for each pathway involved in VSMC
ADRA1 Pathway Associated with HTN and DBP
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Inclusion of genes (e.g. myosin light-chain, myosin light-chain
kinase, etc.) involved downstream of SR calcium release did not
significantly alter the results (data not shown). Literature searches
were used to determine the relevant tissue-specific isoform for
genes that display tissue-dependent isoform expression. Gene
borders were defined using the hg-18 list from UCSC published on
Plink’s website (http://pngu.mgh.harvard.edu/ ˜purcell/plink/
dist/glist-hg18), and adding 20 kb to each side of the range for
inclusion of regulatory regions.
Statistical analyses
Association analyses were performed for blood pressure both as
a dichotomous (hypertensives vs. normotensives) and a continuous
trait. There were 790 hypertensives defined as those with systolic
blood pressure $140 mmHg, diastolic blood pressure
$90 mmHg or on medication at time of exam. When used as a
continuous trait, the observed blood pressure on the 399
hypertensive individuals known to be on antihypertensive medi-
cation were adjusted by adding 15 mmHg to systolic and
10 mmHg to diastolic values [14]. Additive genetic models were
used to fit logistic regression for the hypertension phenotype and
linear regression for the continuous BP trait. Each SNP was coded
as the count or dosage of the minor allele per genotype in both the
logistic and linear regression models, and adjustment was made for
sex, age, age
2 and BMI. For the SNPs on the X chromosome, the
coding involved assigning ‘1’ when the minor allele is the genotype
or ‘0’ when the major allele is the genotype for males since males
are hemizygous. The coding for females is same as for the
autosomal SNPs. Inclusion of sex as covariate in the association
analysis on the X chromosome is equivalent to stratification of the
analysis by sex [15].
Pathway significance. Pathways were assessed for signifi-
cance using the set-based method in Plink v1.07 [16], which
performs well compared to other set-based tests [17]. Briefly, a
threshold R
2 value (for LD) and a PSNP cutoff are specified. An
association analysis is performed on the original dataset, and the
most significant SNP is selected. All SNPs that have R
2 values
above the threshold value are eliminated to prevent the inclusion
of multiple SNPs from the same locus. Then, the next most
significant SNP is selected. The iterative process repeats until the
next selected SNP does not meet the specified PSNP cutoff. Next,
10,000 permuted datasets are created by swapping case and
control labels, and the aforementioned process is repeated for each
permuted dataset. The empirical p-value for the pathway (Ppath)i s
the number of times the permuted set-statistic exceeded the
original dataset-statistic for that pathway. There were a total of 28
unique pathways, for a significance cutoff of Ppath,0.002.
Gene significance. Genes were assessed using the set-based
method in Plink, using the gene as the unit rather than the
pathway. There was a total of 101 unique genes, for a significance
cutoff of Pgene,0.0005.
SNP significance. There was a total of 4,349 unique SNPs,
for a significance cutoff of PSNP,1.15610
25.
ADRA1 Pathway Genetic Risk Model. A risk score was
created using the approach proposed by Morris et al [18]. Alleles
for all significant SNPs within the ADRA1 pathway (40 for
hypertension, 34 for DBP, and 37 for SBP) were summed and
weighted equally to form the denominator (ni), which represents
the number of total alleles. The numerator (ri) represents the
number of unfavorable alleles for each individual. SNPs were
Table 1. Descriptive characteristics of phenotypes among
study participants.
Females Males All
No. (%) 940 (58.2) 674 (41.8) 1614
Age (years) 49.78613.9 47.88615.4 48.99614.5
Weight (kg) 64.09615.3 64.92613.1 64.44614.4
Height (m) 1.5960.1 1.7060.1 1.6460.1
Body mass index (kg/m
2)2 5 . 2 1 65.8 22.4964.2 24.0765.4
Systolic blood pressure (mmHg) 129.96627.7 134.12627.0 131.69627.5
Diastolic blood pressure (mmHg) 80.75616.2 81.94616.7 81.25616.4
Hypertensives (%) 477 (50.7) 320 (47.5) 797 (49.4)
On medication (%) 240 (50.3) 159 (49.7) 399 (50.1)
Values are expressed as mean6SD.
doi:10.1371/journal.pone.0037145.t001
Table 2. Pathway Association Results.
Hypertension DBP SBP
Pathway SNPs N Sig Ppath N Sig Ppath N Sig Ppath
ADRA1 618 40 0.0009* 34 0.0007* 37 0.06
ADRA1, –
receptors
{
588 27 0.03 20 0.01 24 0.52
ADRA2 668 22 0.01 27 0.06 27 0.06
ADRB2 631 22 0.03 29 0.13 28 0.21
ADRB1 610 20 0.04 26 0.09 26 0.20
ET 415 26 0.08 18 0.23 20 0.91
DRD1A 825 42 0.09 40 0.004 47 0.76
AVP1 284 19 0.10 12 0.06 14 0.89
VIP 316 11 0.12 18 0.37 13 0.29
KATP 20 1 0.14 1 0.20 1 0.31
DRD1B 430 13 0.15 23 0.22 23 0.40
ACH 380 13 0.18 23 0.35 16 0.17
AVP2 89 1 0.18 5 0.57 6 0.25
RAA1 312 21 0.20 22 0.58 16 0.41
RAA2 363 26 0.22 26 0.55 19 0.47
PGI2 296 12 0.23 17 0.31 13 0.29
AT2C 965 49 0.23 45 0.73 46 0.85
PUR2 89 4 0.24 1 0.77 4 0.84
NA 807 33 0.25 41 0.68 42 0.71
HIST 325 14 0.27 19 0.25 16 0.12
NAK 444 38 0.28 32 0.19 28 0.11
PUR1 72 2 0.40 2 0.14 1 0.71
PX 72 4 0.45 6 0.16 4 0.05
NO 591 26 0.48 29 0.51 31 0.59
ANP 21 1 0.50 0 1.00 1 0.38
AT2A 144 9 0.51 11 0.37 8 0.15
BNP 20 1 0.52 0 1.00 1 0.40
AT2B 235 12 0.64 20 0.46 13 0.24
CNP 21 0 1.00 1 0.28 0 1.00
*p-value is significant after correction for multiple testing.
{ADRA1, -receptors is the same pathway as ADRA1, with the ADRA1 receptor
genes removed from the model.
Adjustment was made for sex, age, age
2 and BMI for all models.
doi:10.1371/journal.pone.0037145.t002
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the major allele of protective SNPs (OR,1 or beta,0) were
summed to equal ri, because the presence of these alleles would
increase an individual’s risk. An individual’s score (ri/ni) was
calculated as equal to the ratio of number of unfavorable alleles (ri)
carried by the individual to the total number of alleles (ni). The risk
score variable was subsequently categorized into quintiles for
analysis in adjusted regression models.
Results
The study population was 49% hypertensive, 58% female, had a
24.0765.4 mean BMI (kg/m
2), and were 48.99614.5 mean years
of age (Table 1). Pathways were tested for significance using
hypertensive case status, SBP, and DBP as the outcome variables
(Table 2). Only the adrenergic alpha 1 pathway (ADRA1) was
significantly associated with at least one of the outcome variables
after correcting for testing of 28 pathways. The ADRA1 pathway
showed a stronger association with DBP (34/618 SNPs significant,
Ppath,0.0007) and hypertension (40/618 SNPs significant,
Ppath,0.0009) than SBP (37/618 SNPs significant, Ppath,0.06).
The ADRA1 pathway consists of genes involved in epinephrine
and norepinephrine synthesis, genes involved in VSMC signal
transduction leading to intracellular calcium release, and major
regulatory proteins (Figure 1). ADRA1 remained associated with
hypertension (Ppath,0.03) and DBP (Ppath,0.01) even when the
ADRA1 receptor genes (ADRA1A, ADRA1B, ADRA1D) were
removed from the model, indicating multiple genes within the
pathway were responsible for the observed association.
The ADRA1 pathway was further examined at the gene level
(Table 3), including the odds ratio (OR) or beta value and p-value
for the most significant SNP in each gene. PNMT, which catalyzes
the synthesis of epinephrine from norepinephrine, displayed the
strongest association with hypertension (Pgene,0.004), DBP
(Pgene,0.004), and SBP (Pgene,0.009) of any gene in the ADRA1
pathway. Of the three alpha 1 adrenergic receptor isoforms
(ADRA1A, ADRA1B, ADRA1D), ADRA1B showed the strongest
association with hypertension (Pgene,0.005), DBP (Pgene,0.02),
and SBP (Pgene,0.02). Multiple SNPs within both PNMT (3 SNPs)
and ADRA1B (7–8 SNPs) were associated with hypertension, DBP,
and SBP. None of the genes within the ADRA1 pathway had a
significant Pgene value after correction for multiple testing.
Likewise, none of the SNPs within the ADRA1 pathway had a
significant PSNP after multiple testing correction, and other
pathways had SNPs with lower p-values than those in ADRA1
Figure 1. ADRA1 pathway associated genes. Gene names are in italics. Regulators are in circles. TH, tyrosine hydroxylase; DDC, dopa
decarboxylase; DBH, dopamine beta hydroxylase; PNMT, phenylethanolamine N-methyltransferase; ADRA1A, ADRA1B, ADRA1D, adrenergic alpha 1
receptors; GNAQ, guanine nucleotide binding protein, Q; GNA11, guanine nucleotide binding protein, alpha 11; PLCB3, phospholipase C, beta 3;
ITPR1, inositol 1,4,5-triphosphate receptor, type 1; POMC, proopiomelanocortin; COMT, catechol-o-methyltransferase; MAO, monoamine oxidase; RGS
2,4,5, regulator of g-protein signaling.
doi:10.1371/journal.pone.0037145.g001
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ADRA1 was the only significant pathway by a factor of 10
2.
Table 4 shows the effect of varying R
2 and the PSNP-value cutoff
on the association results for the ADRA1 pathway. Significance
under strict values (R
2=0.1, PSNP,0.01) indicates that the
pathway has few SNPs associated with disease, but the associations
are strong. Significance under loose values (R
2=0.8, PSNP,0.05)
indicates that the pathway has many SNPs weakly associated with
disease. The ADRA1 pathway was most strongly associated with
disease under intermediate values (R
2=0.5, PSNP,0.05), suggest-
ing a mixture of strongly associated SNPs and multiple weakly
associated SNPs.
The OR for hypertension, increase in DBP, and increase in SBP
were plotted against quintile of ADRA1 pathway risk score
(Figure 2). OR for hypertension (7.07, 95%CI 4.08–10.41), change
in DBP (11.76 mm Hg, SE 1.29), and change in SBP
(19.54 mm Hg, SE 2.25) all displayed highly significant differences
(p,0.0001) when comparing the lowest quintile risk score with
highest quintile risk score. It is important to emphasize that two
individuals with identical risk scores may have different risk alleles
contributing to the score. Thus, the observed increases in OR for
hypertension and blood pressure with increasing risk score may
not be applicable to the individual level.
Discussion
Our study highlights the potential of applying a pathway-
focused approach to genomic association scans for hypertension.
Twenty-eight pathways were examined for association with
hypertension, SBP, and DBP. Of the pathways examined, only
the ADRA1 pathway remained significantly associated with
hypertension and DBP after correction for multiple testing.
Multiple genes within the ADRA1 pathway were associated with
hypertension and DBP, with the PNMT gene and the ADRA1B
gene displaying the strongest associations. Other pathways
involving the PNMT gene (ADRA2, ADRB1, ADRB2) did not
reach pathway significance, indicating that ADRA1 pathway
association is not an isolated effect of the PNMT gene.
Furthermore, when all SNPs within the ADRA1 receptor genes
(ADRA1A, ADRA1B, ADRA1D) were removed from the model, the
ADRA1 pathway remained associated with hypertension and
DBP, suggesting that the observed pathway association was driven
by genetic variants in several genes.
Given the importance of blood pressure control to human
survival, it is unlikely that the common genetic variants influencing
hypertension have large effect sizes. For example, the largest
hypertension GWAS to date identified 29 SNPs associated with
blood-pressure and hypertension and found that each of the risk
Table 3. Genes in the ADRA1 Pathway.
Hypertension DBP SBP
Gene SNPs N Sig Pgene OR N Sig Pgene Beta N Sig Pgene Beta
TH 4 0 1.00 NA 0 1.00 NA 0 1.00 NA
DDC 84 0 1.00 NA 0 1.00 NA 2 0.15 22.81
DBH 30 1 0.12 1.42 0 1.00 NA 0 1.00 NA
PNMT 9 3 0.004 0.77 3 0.004 22.10 3 0.009 23.21
ADRA1A 59 2 0.30 1.39 4 0.54 1.84 3 0.18 3.16
ADRA1B 30 8 0.005 0.57 7 0.02 24.17 7 0.02 24.24
ADRA1D 33 3 0.19 1.35 2 0.03 2.76 3 0.28 3.47
GNAQ 53 4 0.18 0.77 0 1.00 NA 3 0.62 3.74
GNA11 8 0 1.00 NA 0 1.00 NA 0 1.00 NA
PLCB3 3 0 1.00 NA 0 1.00 NA 0 1.00 NA
ITPR1 208 15 0.10 0.64 12 0.08 24.14 11 0.77 24.50
POMC 13 0 1.00 NA 1 0.33 21.38 1 0.32 22.27
COMT 25 0 1.00 NA 0 1.00 NA 0 1.00 NA
MAOA 28 0 1.00 NA 2 0.27 1.24 0 1.00 NA
MAOB 45 0 1.00 NA 2 0.12 2.74 0 1.00 NA
RGS2 16 2 0.21 1.23 0 1.00 NA 3 0.16 3.12
RGS4 19 1 0.12 2.17 0 1.00 NA 1 0.22 8.35
RGS5 53 1 0.61 0.85 1 0.36 21.55 0 1.00 NA
Adjustment was made for sex, age, age
2 and BMI for all models.
doi:10.1371/journal.pone.0037145.t003
Table 4. Varying R
2 and PSNP cutoffs for the ADRA1 Pathway.
Outcome Conditions R
2 (LD) PSNP cutoff Ppath
Hypertension Default 0.5 .05 0.0009
Hypertension Strict 0.1 .01 0.10
Hypertension Loose 0.8 .05 0.003
SBP Default 0.5 .05 0.06
SBP Strict 0.1 .01 0.19
SBP Loose 0.8 .05 0.07
DBP Default 0.5 .05 0.0007
DBP Strict 0.1 .01 0.03
DBP Loose 0.8 .05 0.003
doi:10.1371/journal.pone.0037145.t004
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than 1 mm Hg [19]. The impact of any single SNP on blood
pressure is small, but the accumulation of SNPs within a causal
pathway could have a larger effect on risk for hypertension. The
pathway approach used in this study examined only a fraction of
the SNPs contained in the human genome. However, these SNPs
were selected because they are within genes involved in pathways
that have been previously linked to hypertension, which
maximizes the likelihood that these SNPs could be associated
with risk for hypertension. Not only does the pathway approach
reduce the likelihood of false positive associations, it is also
restricted solely to pathways linked to the phenotype as opposed to
the genome-wide search approach of GWAS for genetic variation
in blood pressure. The pathway-focused analysis can identify an
accumulation of moderately significant (1022.p.1025) SNPs
within a pathway, a feat that is not often possible using GWAS
because of the high penalty caused by multiple testing. Blood
pressure is a tightly regulated physiologic parameter under high
selective pressure, which makes pathway-focused analysis well
suited for studying the underlying genetic etiology due to its ability
to detect cumulative effects of multiple subtle SNPs within a
pathway. Our study focused on moderately significant SNPs
within pathways with established relevance to hypertension, and it
demonstrated the strengths, weaknesses, and potential for future
application of the pathway approach to hypertension genomic
association scans. It must be emphasized that this study was
neither powered nor intended to identify SNPs that passed the
genome-wide significance threshold, but rather to identify
pathways containing an excess of moderately significant SNPs.
The observed ADRA1 pathway associations in our study have
not been identified in previous GWASs, but they are not
unprecedented in the hypertension genetics literature. None of
the SNPs identified in large-scale hypertension GWAS have been
within the loci for any of the genes in the ADRA1 pathway [19–
21]. However, the ADRA1B receptor has been linked to systolic
blood pressure in a study of 427 young Caucasians [22], and
ADRA1B antagonists (L-765,314, prazosin, terazosin) are com-
monly used to treat and investigate hypertension. A locus on rat
chromosome 10 mapping to the human PNMT locus on
chromosome 17q21–q22 has been associated with blood pressure
regulation in the stroke-prone spontaneously hypertensive rat
[23,24].
One possibility for this discrepancy between large-scale GWAS
and our study is the differing methods used to analyze the genomic
data. GWAS focus on the single nucleotide level, whereas the
pathway approach identifies sets of genes containing multiple
SNPs associated with disease. None of the SNPs identified in our
study was significant at the genome-wide level and they would not
have been detected in a GWAS, but the cumulative effect of
multiple SNPs led to significance at the pathway level. The largest
hypertension GWAS to date found an excess of SNPs with
moderately significant (10
22.p.10
25) associations for hyperten-
sion, and these SNPs more than doubled the proportion of
phenotypic variance that could be explained by significant
(p,5610
29) common variants [19]. The pathway approach
may prove to be an effective method to identify these moderately
significant SNPs. The risk score showed the impact of an excess of
moderately significant risk alleles within the ADRA1 pathway
(Figure 2), although the risk score used in our study may not be a
good measure of risk for an individual.
Another possibility for the discrepancy between previously
published reports and our study is the increased importance of
ancestral genetic background when using the pathway-focused
approach. The pathway approach might be population specific,
because the likelihood of having the same set of genetic variants
within a pathway is low between populations. McCarthy showed
that changes in minor allele frequency drastically changes
statistical power to detect a single SNP [25]. It is likely that
statistical power would vary even more dramatically between
populations when using the pathway approach because many
SNPs are tested concurrently.
One promise of pathway analysis and genomics in general, is
the ability to stratify patients based on their own genetic
information rather than the generalized category of self-identified
race. The controversy [26] over the response of African-
Americans to angiotensin-converting enzyme (ACE) inhibitors
highlights the need to further refine our understanding of the
genetic determinants of hypertension and therapeutics. Variants in
the angiotensinogen gene are associated with hypertension in
whites [27], but not in African-Americans or Yorubas [28]. This
Figure 2. Line graphs representing the ADRA1 pathway genetic
risk model for DBP, SBP, and hypertension (HTN). The risk score
was divided into quintiles, with the reference category being the lowest
risk score quintile. * P,0.05. ** P,0.005. ***P,0.0001.
doi:10.1371/journal.pone.0037145.g002
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response to ACE inhibitors between whites and African-Ameri-
cans. The results have been equivocal [29,30], yet ACE inhibitor
usage has been avoided in some African-American patients under
the presumption of racial differences in response [31]. Even if
there were a true difference in response, it is likely that some
African-Americans would respond better to ACE inhibitors than
some European-Americans due to wide within-population varia-
tion [32]. Thus. the difficulty in predicting race specific responses
to drugs demands a more finely tuned method of stratification
than race. Our current study of 1,614 Yorubas is unlikely to settle
any larger debates. However, we have shown that pathway
focused analysis can be used to detect accumulations of moderately
significant SNPs within pathways, and that the ADRA1 pathway is
associated with hypertension in our sample. The use of pathway
analysis to identify novel variants associated with hypertension is
an initial step in refining the pathogenesis of hypertension to the
individual level rather than using broader, less accurate racial
categorizations.
There are several limitations to the pathway approach taken in
this study. First, there is an increased need for adequate SNP
coverage due to testing of a limited area of the genome. However,
the plummeting cost of genomic sequencing in the near future
should gradually reduce concerns over inadequate SNP coverage.
Second, the nature of pathway selection is subjective on several
levels: (1) the level of evidence needed for inclusion of pathways in
the study, (2) the set of genes included in the study, and (3) the
length of putative regulatory regions included upstream and
downstream from each gene. As more hypertension pathway
studies are undertaken, the set of pathways, genes, and gene
regions should become more comprehensive and then a consensus
list could be produced, thereby standardizing the process of
selection. Third, our study may be vulnerable to issues of external
validity due to the increased importance of common ancestral
genetic background in pathway study populations. Our results
would need to be verified in similar and other populations to
determine the extent to which pathway studies can be generalized.
Finally, it is also worth noting that the significance of individual
SNPs in this study should be taken with caution, since a broader
approach to pathway selection would have resulted in testing more
SNPs with stiffer penalties for multiple testing.
We have identified an association for hypertension and DBP in
the ADRA1 pathway, and we have illustrated the potential of the
pathway-focused approach to investigate genetic variation in
hypertension. Unlike GWAS, targeting of selected pathways
cannot be used to discover new biological mechanisms of disease.
However, the pathway approach has several distinct advantages
over the genome-wide approach, including ease of interpretation,
minimization of multiple testing, epistasis studies in larger study
populations [33], and the potential to quickly translate genetic
polymorphisms associated with disease into targeted therapies.
The pathway approach is an excellent option for detecting
moderately significant SNPs, an intriguing source of genetic
variation whose importance was implicated in the largest
hypertension GWAS to date [19]. Hypertension is especially
amenable to the pathway approach because there are many
treatment options available for hypertensive patients. Targeted
therapies that operate on pathways associated with hypertension
could reduce clinical uncertainty of treating hypertension.
Although the results from this study must be replicated in similar
populations, this pathway-focused genomic association study
shows promise as a new approach to revealing the genetic
underpinnings of hypertension.
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